You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The companies had agreed in early 2018 to collaborate on the development of technologies to support precision oncology initiatives, but Roche said "priorities" have changed.
The LCD will provide coverage for the Decipher Prostate Biopsy genomic test for men with both favorable and unfavorable intermediate-risk prostate cancer.
The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.
The extended deal covers multiple blood cancer and solid tumor indications and will leverage several HalioDx technologies and approaches.
The firms will codevelop companion diagnostics for anti-PD1/PD-L1 immunotherapy treatments for cancer.
Promega's microsatellite instability technology will be used to develop an on-label, solid tumor companion diagnostic for pembrolizumab.
The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
The Voyage study is designed to enroll more than 150,000 people and will follow participants for at least seven years.
The grant will co-fund a year-long project to validate Biofidelity's chemistry to detect mutations used to guide non-small-cell lung cancer treatment.
In one of its partnerships, Gestalt will work to integrate Flagship Bioscience's machine learning tools to enable cancer biomarker detection.
The firm hopes to return fewer VUS in its test reports and to accelerate the resolution of uncertain results issued to patients in that past.
The company operates three subsidiaries including Helomics, which provides tumor-analysis services for treatment personalization and new drug development.
The assay was developed in partnership with Merck and is intended as a companion diagnostic for that firm's anti-PD-L1 immunotherapy.
The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.
The companies will use their respective technologies to identify inhibitors of cancer-associated gene targets and optimize their use as therapeutics.
The companies will use Freenome's platform to identify cancer patients who are most likely to respond to treatment with ADC's loncastuximab tesirine.
The two companies will work together to bring the point-of-care pretreatment diagnostic based on the XDX-01 biomarker to market in 2020.
Onconova will use Mission Bio's Tapestri platform to study rigosertib — a drug that Onconova is developing — to target the RAS mutation in myelodysplastic syndromes.
The diagnostic can now be used to identify patients with esophageal squamous cell carcinoma who may benefit from first-line treatment with Keytruda.
The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.